• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Optimizing the Transition to Biosimilars: Considerations for Payers

home / insights / optimizing-the-transition-to-biosimilars-considerations-for-payers

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

© 2023 MJH Life Sciences
All rights reserved.